Schizophrenia Clinical Trial
— PROSIGOOfficial title:
Predictors of Persistence in Patients With Schizophrenia Treated With Once-monthly Aripiprazole Long-acting Injection in the Spanish Clinical Practice: a Retrospective, Observational Study
NCT number | NCT03130478 |
Other study ID # | 031-307-00162 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | July 18, 2017 |
Est. completion date | July 30, 2018 |
Verified date | August 2018 |
Source | Otsuka Pharmaceutical Europe Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This is an observational, retrospective, non-interventional study that will include schizophrenic patients who were initiated on AOM treatment during an schizophrenia-related hospitalisation at least 6 months before data collection and in a real clinical practice setting.
Status | Completed |
Enrollment | 119 |
Est. completion date | July 30, 2018 |
Est. primary completion date | July 30, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Adult patients (age = 18 years at the time of AOM initiation). 2. Diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders V available at start of AOM treatment, and confirmed by the current investigator. 3. Having been hospitalized for an acute psychotic relapse and having been initiated with AOM as primary maintenance antipsychotic treatment, in accordance with the terms of the marketing authorisation, during the hospitalisation, at least 6 months before the inclusion and before November 1st 2016 (and up to January 2016 at the earliest). 4. Provision of patient informed consent unless a) not required by local regulations, b) it would take a non-reasonable effort* or c) if the source patient is deceased or untraceable. - A reasonable effort is defined as 3 contact attempts separated by 3 weeks. All efforts to obtain the informed consent, reasonable or not, shall be registered in the medical history of the patient to be used as documental source. If allowable by Ethics Committees, provision of oral (e.g., by phone) instead of written consent is also possible for patients with retrospective assessment only. Exclusion Criteria: 1. The patient has a psychiatric disorder other than schizophrenia which is established as the primary diagnosis 2. Chronically hospitalized patients at time of AOM initiation. 3. Patients who receive, after AOM initiation, a concomitant oral antipsychotic treatment for more than 4 weeks (with the exception of low dose quetiapine)* * Low dose quetiapine is acceptable up to a maximum of 150 mg daily only for sedative purposes, but not for the induction of any psychopharmacological effect on mood and/or psychosis. 4. Participation in an interventional clinical trial during the retrospective follow-up period. |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Universitario de Álava | Alava | |
Spain | Hospital Fundación Alcorcón | Alcorcón | |
Spain | Numància Salut Mental (Parc Sanitari St Joan de Deu) | Barcelona | |
Spain | Hospital de Ciudad Real | Ciudad Real | |
Spain | Hospital IAS Girona | Girona | |
Spain | Hospital Universitari Bellvitge | L'Hospitalet de Llobregat | |
Spain | Complejo Asistencial Universitario de Leon | Leon | |
Spain | Fundación Jiménez Díaz | Madrid | |
Spain | HGU Gregorio Marañón | Madrid | |
Spain | Hospital Infanta Leonor | Madrid | |
Spain | Hospital Carlos Haya | Malaga | |
Spain | Parc Sanitari St. Joan de Deu (St. Boi) | Sant Boi de Llobregat | |
Spain | Hospital Santiago de Compostela | Santiago de Compostela | |
Spain | Hospital Universitario Virgen del Rocío | Sevilla | |
Spain | Hospital Álvaro Cunqueiro | Vigo |
Lead Sponsor | Collaborator |
---|---|
Otsuka Pharmaceutical Europe Ltd |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Persistence (days) with aripiprazole once-monthly | To describe in real-world practice the impact of demographic and clinical characteristics on persistence in patients with schizophrenia initiated on aripiprazole once-monthly (AOM) during an inpatient stay due to an acute schizophrenia relapse. | First 6 months after treatment initiation | |
Secondary | Description of reasons of treatment discontinuation (number of discontinuations per reason) | Date of AOM interruption or discontinuation and reason for discontinuation | From treatment initiation up to patient inclusion (minimum 6 months) | |
Secondary | Change over time in Clinical Global Impressions - Severity (CGI-S) scale | Clinical Global Impressions - Severity (CGI-S) scale at index date (if available in patient's file or estimated by the investigator according to medical records) and CGI-S up to patient's inclusion (if available in patients' file or estimated by the investigator according to medical records). CGI-S up to patient's inclusion (if available in patients' file or estimated by the investigator according to medical records). | From treatment initiation up to patient inclusion (minimum 6 months) | |
Secondary | Change over time in the Brief Psychiatric Rating Scale (BPRS) | Brief Psychiatric Rating Scale (BPRS) at index date (if available in patient's file) and BPRS up to the patient's inclusion (if available in patients' file). | From treatment initiation up to patient inclusion (minimum 6 months) | |
Secondary | Description of AOM treatment (starting dose and dose adjustments, number of injections, prior and concomitant medications, settings) | Description of AOM treatment (starting dose and dose adjustments, number of injections, prior and concomitant medications, settings) | From treatment initiation up to patient inclusion (minimum 6 months) | |
Secondary | Description of health resource use (HRU) related to schizophrenia (hospitalisations, medications, non-pharmacological therapies, outpatient visits, procedures) | Description of health resource use (HRU) related to schizophrenia (hospitalisations, medications, non-pharmacological therapies, outpatient visits, procedures) | From treatment initiation up to patient inclusion (minimum 6 months) | |
Secondary | Description of non-pharmacological interventions aiming to improve functionality (types, numbers of patients per type) | Description of non-pharmacological interventions aiming to improve functionality (including, if applicable, initiation and end dates of Institutional support, Cognitive behavioural therapy (CBT), Assertive Community Treatment/Case management, Group or individual psychoeducation, Family psychoeducation, Group or individual psychotherapy, Structured rehabilitation program, Occupational support, Severe mental illness management program) | From treatment initiation up to patient inclusion (minimum 6 months) | |
Secondary | Description of patterns of alcohol and drug abuse and/or dependence (patterns of drug abuse, type of substance, frequency of consumption) | To qualitatively describe patterns of drug abuse and/or dependence | From treatment initiation up to patient inclusion (minimum 6 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |